Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, Cathleen Lutz, PhD, vice president of the Rare Disease Translational Center at the Jackson Laboratory, provided comment on a recently published study which unveiled that stathmin-2 loss leads to neurofilament-dependent axonal collapse in patients with amyotrophic lateral sclerosis (ALS). Lutz offered insight on the role stathmin-2 may have in this disease, the questions that still remain, and whether restoration of stathmin-2 may be an attractive therapeutic approach. Furthermore, she spoke on the potential of this protein as a disease-modifying biomarker and whether it may be incorporated in trials in the near future. 

Episode Breakdown:

1:15 – Idea behind studying stathmin-2

2:45 – Overviewing study results

7:05 – Next steps in extending this research

8:40 – Neurology News Minute

11:30 – Stathmin-2's connection with neurofilament light

12:55 – Potential of stathmin-2 as ALS-specific biomarker

14:45 – Future use of stathmin-2 in clinical trials

15:30 – Closing thoughts

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.